Table 1.

Description of 1,183 patients who were diagnosed with primary lung cancer and received platinum-based chemotherapy

Characteristics of diagnosis and treatmentValues and percentages
Age at diagnosis
 Mean (SD)62.3 (10.34)
 Median (range)63.0 (27.0–88.0)
Gender, n (%)
 Female527 (44.5%)
 Male656 (55.5%)
Cigarette smoking status
 Never192 (16.2%)
 Former smokers560 (47.3%)
 Current smokers431 (36.5%)
Lung cancer stagea
 Unknown
 SCLC
  Limited129 (10.9%)
  Extensive93 (7.9%)
 NSCLC
  I123 (10.4%)
  II82 (6.9%)
  III403 (34.1%)
  IV353 (29.8%)
Histologic cell type
 Adenocarcinoma550 (46.5%)
 Squamous cell carcinoma194 (16.4%)
 Small cell carcinoma222 (18.8%)
 Large cell carcinoma39 (3.3%)
 Mixed and unspecified NSCLC167 (14.1%)
 Carcinoid or salivary gland tumors11 (0.9%)
Tumor differentiation grade
 Nongradable or unknown80 (6.8%)
 Well differentiated91 (7.7%)
 Moderately differentiated392 (33.1%)
 Poor/undifferentiated620 (52.4)
Treatment modality
 Only platinum drugs302 (25.5%)
 Surgery and platinum drugs192 (16.2%)
 Radiation and platinum drugs455 (38.5%)
 Surgery, radiation, and platinum drugs234 (19.8%)
  • aStage for NSCLC is described on the basis of the tumor-node-metastasis classification. The small cell lung cancer stage is described as suggested by the American Cancer Society as either “extensive” or “limited.”